**Title:** Childhood immunization uptake determinants in Kinshasa, DRC: ordered regressions to assess timely infant vaccines administered at birth and six-weeks.

**Co-Authors**

Alix Boisson-Walsh1, Peyton Thompson2, Bruce Fried3, Christopher Michael Shea4, Patrick Ngimbi5, Fidéle Lumande6, Martine Tabala7, Kashamuka Mwandagalirwa8, ﻿Pélagie Babakazo9, Marisa Elaine Domino10, Marcel Yotebieng11

1Department of Health Policy and Management, Gillings School of Global Public Health, The University of North Carolina, Chapel Hill, NC, 27599, USA, [aboisson@unc.edu](mailto:aboisson@unc.edu).

2Division of Infectious Diseases, Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27599, USA, [peyton\_thompson@med.unc.edu](mailto:peyton_thompson@med.unc.edu).

3Department of Health Policy and Management, Gillings School of Global Public Health, The University of North Carolina, Chapel Hill, NC, 27599, USA, [bruce\_fried@unc.edu](mailto:bruce_fried@unc.edu).

4Department of Health Policy and Management, Gillings School of Global Public Health, The University of North Carolina, Chapel Hill, NC, 27599, USA, [chris\_shea@unc.edu](mailto:chris_shea@unc.edu).

5Ecole de Santé Publique de Kinshasa, Kinshasa, Democratic Republic of the Congo, [patrickngimbi1@gmail.com](mailto:patrickngimbi1@gmail.com).

6Ecole de Santé Publique de Kinshasa, Kinshasa, Democratic Republic of the Congo, [lumandefidlkas@gmail.com](mailto:lumandefidlkas@gmail.com).

7Ecole de Santé Publique de Kinshasa, Kinshasa, Democratic Republic of the Congo, [martinetabala@yahoo.fr](mailto:martinetabala@yahoo.fr).

8Ecole de Santé Publique de Kinshasa, Kinshasa, Democratic Republic of the Congo, [mkasamuka@yahoo.fr](mailto:mkasamuka@yahoo.fr).

9Ecole de Santé Publique de Kinshasa, Kinshasa, Democratic Republic of the Congo, [pbabakazo@gmail.com](mailto:pbabakazo@gmail.com).

10Center for Health Information and Research, College of Health Solutions, Arizona State University, Phoenix, AZ, 85004, USA, [marisa.domino@asu.edu](mailto:marisa.domino@asu.edu).

11Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, 10461, USA, [marcel.yotebieng@einsteinmed.edu](mailto:marcel.yotebieng@einsteinmed.edu).

**Corresponding author:** Alix Boisson1

1Department of Health Policy and Management, Gillings School of Global Public Health, The University of North Carolina, Chapel Hill, NC, 27599, USA, [aboisson@unc.edu](mailto:aboisson@unc.edu).

**Abstract**

**Background:**Despite global efforts to reduce preventable childhood illness by distributing infant vaccines, immunization coverage in sub-Saharan African settings remains low. Further, timely administration of vaccines at birth – tuberculosis (Bacille Calmette-Guérin [BCG]) and polio (OPV0) – remains inconsistent. As countries such as Democratic Republic of the Congo (DRC) prepare to add yet another birth-dose vaccine to their immunization schedule, this study aims to improve current and future birth-dose immunization coverage by understanding the determinants of infants receiving vaccinations within the national timeframe.

**Methods:**The study used two ordered regression models to assess barriers to timely BCG and first round of the hepatitis B (HepB3) immunization series across multiple time points using the Andersen Behavioral Model to conceptualize determinants at various levels. The assessment leveraged survey data collected during a continuous quality improvement study (NCT03048669) conducted in 105 maternity centers throughout Kinshasa Province, DRC. The final sample included 2,398 (BCG analysis) and 2,268 (HepB3 analysis) women-infant dyads living with HIV.

**Results:**Between 2016 and 2020, 1,981 infants (82.6%) received the BCG vaccine, and 1,551 (68.4%) received the first dose of HepB3 vaccine. Of those who received the BCG vaccine, 26.3%, 43.5%, and 12.8% received BCG within 24 hours, between one and seven days, and between one and 14 weeks, respectively. Of infants who received the HepB3 vaccine, 22.4% received it within six weeks, and 46% between six and 14 weeks of life. Many factors were positively associated with BCG uptake, including higher maternal education, household wealth, higher facility general readiness score, and religious-affiliated facility ownership. The factors influencing HepB3 uptake included older maternal age, higher education level, household wealth, transport by taxi to a facility, higher facility general and immunization readiness scores, and religious-affiliated facility ownership.

**Conclusion:**This study demonstrated that the study participants’ uptake of vaccines was consistent with the country average, but not in a timely manner. Various factors were associated with timely uptake of BCG and HepB3 vaccines. These findings suggest that investment to strengthen the vaccine delivery system might improve timely vaccine uptake and equity in vaccine coverage.

**Keywords:** Childhood vaccination, Immunization, hepatitis B virus, hepatitis B birth-dose vaccine, tuberculosis, BCG, Vaccine distribution system, Expectant mothers, Health care workers, Intervention, Democratic Republic of the Congo

**BACKGROUND**

Childhood immunization against hepatitis B virus (HBV) was introduced to national vaccine schedules globally in the 1980s(1) but not instituted in the African continent until the early 2000s.(1–3) Accordingly, the prevalence of chronic HBV and its complications is still unacceptably high in sub-Saharan Africa (SSA). The World Health Organization (WHO) estimates that chronic hepatitis infects over 60 million individuals in SSA,(4) and the majority are unaware that they are carriers.(5) If infected at birth via mother-to-child transmission (MTCT), an infant has a 70-90% chance of developing chronic HBV infection and a 25% chance of mortality.(6) The ‘timely’ administration of HBV birth-dose vaccine (HepB-BD) – administered within the first 24 hours after delivery and followed by additional vaccine doses – can prevent the overwhelming majority of MTCT cases.(7–9) Yet, in most of SSA, infants do not receive their first dose of the HBV vaccine series (HepB3) until six weeks, leaving them vulnerable to infection via MTCT. Timely receipt of HepB-BD is crucial in preventing MTCT. In a Cameroonian study of infants born to HBV surface antigen (HBsAg)-positive mothers, those who received HepB-BD within the first 24 hours were found to have a 1.4% lower prevalence of HBsAg than those who received it 24-47 hours after birth, and an 11.1% lower prevalence than those who received it 48-96 hours after birth.(10) In addition, the risk of transmission among infants born to HBsAg-positive mothers was found to be eight times higher for those who received HepB-BD more than seven days after birth compared to those who received it within the first three days of life,(11) highlighting the importance of timely uptake.

Such high-burden countries as the Democratic Republic of the Congo (DRC) are preparing to add HepB-BD in their national immunization schedule for administration alongside other routine birth-dose (BD) vaccines–oral polio (OPV0) and tuberculosis (Bacille Calmette-Guérin [BCG]).(12) However, effective implementation of BD vaccination is challenging in the SSA context. Of the 13 countries in the region that have already introduced HepB-BD into national policy, the reported coverage within 24h after birth is only 10%.(13,14)(15)A study in the Gambia found that despite the availability of HepB-BD between 2004 and 2014, only 1.1% of infants received the vaccine within 24 hours and only 5.4% by seven days after delivery.(16) These challenges are not unique to HepB-BD. A study in Kinshasa Province across health facilities highlighted significant challenges to the timely delivery of existing BD vaccines to newborns. Major determinants of the timely uptake of BCG and OPV0 included facility-level administration logistics, vaccine stockouts, and vaccine wariness and hesitation.(17) The current DRC national immunization schedule defines timely delivery of BCG and OPV0 BD vaccines as within the first seven days of life. Yet, ongoing challenges continue to impede timely BD delivery. Given these challenges, to introduce HepB-BD to the immunization schedule, facilities will require vaccine delivery strategies to proactively address barriers to administering three BD vaccines in an infant’s first 24 hours of life. The DRC’s national immunization schedule currently awaits the introduction of HepB-BD; for the time being, the first round of HepB3 is provided at six weeks of age.(18) In such contexts, identifying determinants of timely administration of current BD vaccines – especially BCG, which is administered by an injectable method like HepB-BD, rather than orally like OPV0 – can provide proximal and prospective insight into challenges to future timely HepB-BD uptake.

In the present study, we employ the Andersen Behavioral Health Model (BHM), used in previous immunization systems research, to categorize and understand the determinants of vaccine uptake.(19) The BHM addresses barriers to access and utilization at three levels: external environment, predisposing characteristics, and enabling resources, allowing us to investigate barriers to vaccine uptake at both the individual and facility levels. We must understand the determinants of infant receipt of timely vaccination to improve current and future BD immunization coverage. Therefore, we analyzed vital information about barriers and facilitators to the uptake of infant vaccines at multiple time points. Few studies assess barriers to timely first-round immunization at the individual and facility levels across multiple time points, and no study does so with the intent to improve future streamlined and timely uptake of HepB-BD.

**METHODS**

**Study design and setting.**

The assessment leveraged de-identified survey data collected during a continuous quality improvement (CQI) initiative study conducted at 105 maternity centers throughout the Kinshasa Province, DRC. The parent study was designed to assess the impact of continuous quality improvement interventions on long-term outcomes of antiretroviral therapy among pregnant and breastfeeding women. Therefore, eligible participants living with HIV were enrolled anytime during pregnancy, after delivery, or during well-child visits in postpartum at the select facilities.

Mother-infant pairs were excluded from this analysis if the mother or infant died during the study period, or if the child was aborted during the study period. The original study sample included 2,875 expectant mothers enrolled in the cohort study from 2016-2020 during antenatal care (ANC) or postpartum visits. A face-to-face interview was conducted with all enrolled participants at registration and subsequent visits at the following time points: delivery (for pre-delivery enrolees), six weeks, six months, 12 months, 18-24 months, and 24+ months postpartum. The study staff collected information on the mother-infant pair at delivery. The infant's vaccination status was verified at each follow-up visit using vaccination cards and the vaccination registry in the clinic. Vaccine cards recorded the date of infant vaccines contemporaneously, so it was possible to calculate a precise number of days between the infant's birthday and vaccine date. Assessments about facility capacity and inventory were collected through interviews with facility managers and staff at each of the 105 facilities. The study selected the three clinics with the highest patient volume in each of the 35 health zones of the Kinshasa province. Mothers were eligible for inclusion in this analysis if they were enrolled in the parent study.(20)

**Variables.**

The outcome measure of interest was infant vaccination status. We divided the outcome measure, BCG vaccine status into four categories: within 24 hours of delivery, between one and seven days, or one week to 14 weeks; versus those who never received the BCG vaccine during the study period. The 14-week mark represents the moment of advised completion of an infant’s immunization schedule (**Figure 1**). HBV vaccination status is divided into three categories: within six weeks, six to 14 weeks, and no uptake during the study period. The study team verified the vaccine status of all infants during verbal interviews with mothers and per review of immunization cards.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Figure 1.** Current routine immunization schedule that begins at birth to 14 weeks, DRC 2022 | | | | | |
|  |  | Age | | | |
| Vaccine | Disease | Birth | 6 weeks | 10 weeks | 14 weeks |
| Bacille de Calmette et Guérin (BCG) vaccine | Tuberculosis |  |  |  |  |
| Oral Polio Vaccine (OPV) | Poliomyelitis |  |  |  |  |
| Pentavalent vaccine | ﻿Diphtheria, Pertussis, Tetanus, H. influenza type b, Hepatitis B |  |  |  |  |

*This figure is not comprehensive of all infant vaccines in the DRC, but indicate only the current hepatitis B vaccine and vaccines administered at birth*

Covariates were selected based on existing literature about determinants of vaccine uptake at the community and facility levels.(19,21,22) The framework for variable selection was based on Andersen’s BHM to examine factors associated with vaccine utilization. The explanatory variables fell under the three BHM categories.

1. The external environment included the WHO General Service Availability and Readiness Assessment (SARA),(23) the WHO Immunization Services and Availability Assessment, facility type, ownership, and location – all assessed at the facility level. SARA was designed as a systematic survey to assess health facility service delivery, while the immunization service availability assessment was immunization service specific. Both scales consist of pre-selected tracer items within specific domains, which were carefully chosen and validated by service delivery experts. These domains represent essential treatment or care areas. Each item is binary, indicating the observed availability of the particular score on the day of the study team's facility visit. The general readiness scale is generated using four general service domains: basic amenities (6 items), basic equipment (6 items), standard precautions (9 items), and diagnostic capacity (8 items). The immunization readiness scale is composed of two domains: immunization service availability (6 items) and readiness (10 items). During the study, our staff observed the availability of tracer items in each facility. By calculating the mean composite score of the observed items within each domain, we derived a general readiness score and an immunization readiness score for each facility on a 10-point scale.
2. Predisposing characteristics included the infant’s birth order, mother’s age, marital status, and mother’s education level.
3. Enabling factors included the mother’s wealth index score and whether the mother traveled to the facility by foot or by transport**. Table 1** includes more information about the covariates and their distributions.

**Statistical analysis.**

We used multivariate ordered logistic regressions to run two versions of our analysis. Model I examined current BCG BD uptake, while Model II examined current HepB3 vaccine series uptake. With Model I, we examined determinants of current BD vaccines to anticipate barriers to future HepB-BD uptake. BCG uptake was the chosen proxy rather than OPV0 uptake because the injectable method of administration of the vaccine more closely approximated that of future HepB-BD than the orally administered polio vaccine. Model II measured determinants of the uptake of the first dose of HepB3, currently administered at six weeks of age in the DRC.

For model specifications, we used Akaike’s Information Criterion (AIC) to compare alternative functional forms and select the final model. Various functional forms of the continuous variables, including quadratic and categorical forms, were compared through an iterative approach. If a functional form was selected for one variable, it was retained for subsequent comparisons. Model fit was examined for both models, and the best functional forms with the minimum AIC were selected independently. Findings were reported in average marginal effects with delta-standard methods.

Both human error by vaccine staff conducting the interviews and loss-to-follow-up (LTFU) led to missing vaccine information across all time points for BCG status (missing, n = 239; LTFU, n = 248) and HepB3 status (missing, n = 369; LTFU, n = 281). LTFU was only measured among the participants who had not yet vaccinated their infants. We conducted two sets of sensitivity analyses for each outcome variable, BCG and HepB3, (a total of four analyses) to assess the robustness of the results of a full-case analysis against the alternative scenarios, including those with all missing or LTFU-specific information. The first set of analyses was defined by increasing the sample size to include participants with missing vaccine information across all time points as ‘not vaccinated’ or as a distinct category. The second set of analyses included only the LTFU-specific observations as ‘not vaccinated’ or as a distinct category. We found that a model with LTFU weights had directionality and magnitude in accordance with the majority of the models included in both sets of sensitivity analyses and therefore reported adjusted results accounting for LTFU.

**RESULTS**

**Sample characteristics.**

Between November 2016 and July 2020, the parent study enrolled 2,875 participants at 105 facilities. Of the enrolled participants, 56 mothers died, and 172 infants died or were aborted during the study period and were thus excluded from the analysis. A total of 239 mother-infant pairs did not provide BCG vaccine data, and 369 did not provide HepB3 vaccine information across any of the six follow-up visits after enrollment; these pairs were excluded from the analysis. The final sample with complete information included 2,398 (BCG analysis) and 2,268 (HepB3 analysis) women-infant dyads. Complete sample characteristics aggregated by the moment of the first infant vaccine can be found in **Table 2.**

Of the participants with vaccine data, 1,981 (82.6%) received a BCG vaccine, and 1,551 (68.4%) received a HepB3 vaccine. Of those who received the BCG vaccine, 630 (26.3%) of the participants received it within 24 hours, 1,044 (43.5%) received it between one and seven days, and 307 (12.8%) received it between one and 14 weeks. Of infants who received the first dose of HepB3 vaccine, 347 (22.4%) received it within six weeks, and 713 (46%) between six and 14 weeks of life.

In terms of predisposing characteristics, overall, the mean age of the mothers was 31 years old (S.D. = 6.099), and 1,705 (71.2%) mothers were married. Mothers had a median of four children (IQR: 2-5 children) and had 11 years of education (IQR: 9-12 years). For enabling factors, of the total eligible sample, 262 (11.1%) women fell within the lowest wealth quartile versus 523 (21.8%) who fell within the highest. 1,558 (65%) of the women traveled to the facility by taxi (or other forms of transportation) rather than by foot.In terms of the external environment, overall, 1399 (58.3%) women sought care at health centers instead of hospitals, 1,349 (56.3%) women received care at a religiously-affiliated facility, and 1,457 (60.8%) women visited urban facilities. In addition, the median score for a mother’s facility where she sought care was 6.75 (IQR: 6.12-7.39) on the general readiness scale and 6.11 (IQR: 5-6.67) on the immunization readiness scale.

**Model I. Determinants of the uptake of BCG BD vaccine**

**Table 3** presents the results from the ordered logit analyses, which estimated how vaccine uptake at different time points was related to factors influencing the respondent at the predisposing, enabling, and external levels.

In terms of predisposing characteristics, within our sample, every additional year of a mother’s education was associated with a greater rate of earlier vaccination. For instance, an additional year of education was associated with a 0.48 percentage point increase in the probability that a mother would vaccinate her infant within 24 hours of delivery and a 0.52 percentage point decrease in the probability of never vaccinating her infant (p < 0.05).

At the enabling level, household wealth index scores within the second quantile (compared to the fourth, and highest, wealth quantile) were associated with a 7.0 percentage point decrease in probability of timely uptake (p < 0.001) and a 7.9 percentage point increase in the probability of never vaccinating their infant (p < 0.001), see **Table 3.**

For the external environment, higher general readiness scores were associated with timely uptake. A one-point increase in a facility’s general readiness score was associated with a 1.7 percentage point increase in the probability of vaccination within 24 hours (p < 0.01) and a 2.6 percentage point decrease in the probability of never vaccinating an infant (p < 0.01). In addition, visiting religious-affiliated facilities compared to public facilities was significantly associated with receipt of timely BCG (4.2 percentage point increase in vaccination by 24 hours) (p < 0.01) and a 4.9 percentage point decrease in never receiving it (p < 0.01). In addition, religious-affiliated facilities were associated with an 8 percentage point decrease in the probability of vaccine uptake from one to seven days compared to private or other facilities (p < 0.001).

**Model II. Determinants of the uptake of HepB vaccine**

Similar to BCG vaccine uptake, factors that affected the timely uptake of the HepB3 vaccine series varied across all three levels of the BHM.

In terms of predisposing characteristics, within the study sample, every additional year increase in a mother’s age was associated with a 0.21 percentage point increase in the probability of an infant being vaccinated within six weeks and a 0.31 percentage point decrease in the probability of an infant not ever being vaccinated (p < 0.05). Every additional year of a mother’s educational attainment was associated with a 0.77 percentage point increase in the probability that she would vaccinate her infant within six weeks of delivery (p < 0.001) and a 1.2 percentage point decrease in the probability of never vaccinating her infant (p < 0.001).

Within the enabling factors category, household wealth index scores within the second quantile, compared to the fourth and highest wealth quantile, were associated with a 5.3 percentage point decrease in the probability of taking up timely vaccines (p < 0.001) and an 8.2 percentage point increase in the probability of never vaccinating their infant (p < 0.001). Further, among the study sample, using a form of transportation other than walking to travel to the facility was associated with a 2.5 percentage point decrease in the probability of vaccination within six weeks (p < 0.05) and a 3.7 percentage point increase in no vaccination (p < 0.05).

At the external level, a one-point increase in a facility’s immunization readiness score was associated with a 5.3 percentage point increase in the probability of vaccination within 14 weeks (p < 0.01). In addition, an additional point increase in a facility’s general readiness score was associated with a 5.2 percentage point decrease in the probability of an infant never having been vaccinated (p < 0.001). Finally, visiting religious-affiliated facilities, compared to public facilities, was associated with an 8.9 percentage point decrease in the probability of vaccine uptake at 6 weeks (p < 0.001).

**DISCUSSION**

In this study, we investigated the factors associated with timely infant immunization in 105 facilities in Kinshasa Province using a cohort of HIV-positive pregnant women and their infants. We observed similar immunization coverage for BCG (82.6%) and the first dose of HepB3 (68.4%) compared to the WHO/UNICEF estimates of national immunization coverage averaged from 2017-20 (84.5% and 71.3%, respectively).(24)

We observed a strong positive association of factors across all three Andersen BHM categories (predisposing characteristics, enabling factors, and external environment) with timely uptake of both vaccines, BCG and HepB3.Our analyses highlight the importance of considering the effect of determinants at different levels and time intervals. The implication is that policymakers in the DRC can be more focused on implementing vaccine uptake strategies depending on their target group. For example, we identified significant determinants of timely uptake of both BCG and HepB3 at the external environmental level, focusing on intervenable facility characteristics.

Higher general readiness scores and attending a religiously affiliated facility were independently associated with both BCG and HepB3 timely uptake, a finding that aligns with previous studies highlighting vaccine storage and stockout challenges in the DRC.(17,25) In prior work, lower general facility readiness scores have been reported as barriers to timely immunization.(26) Therefore, new vaccine introduction strategies at the facility level should prioritize contributions to general readiness, such as workforce and operations, and immunization readiness, such as reliable availability of vaccines at each facility. Ensuring adequate supply prevents stockouts, which in turn prevents unnecessary/unproductive visits to a facility. This could also bring more equity as it reduces costs for families who live further away from the facility.

In addition, visits to public facilities were negatively and independently associated with timely uptake of BCG compared with visits to religiously-affiliated facilities. In contrast, visits to private, non-religious facilities, as compared to religious facilities, were positively associated with timely uptake of both BCG and HepB3. Previous studies on immunization uptake in SSA have cited a facility’s religious affiliation driving a mother’s choice to seek care there.(17) In terms of private facilities, studies show that mothers visiting private facilities tend to be of higher income levels,(27) a factor that was positively associated with timely vaccine uptake and may explain our findings. Future research could examine the reasons that vaccination rates are higher among those who select private facilities.

Within the category of predisposing characteristics, we found that the mother's educational attainment and age at the time of enrollment were positively associated with the timely uptake of vaccines, which indicated that knowledge, awareness, and experience with preventative care were vital for timely vaccine uptake. A mother's education level is an established predictor of infant immunization in low- and middle-income countries (19,28–30) and education is a valuable solution to overcome challenges to vaccine uptake.(31,32) Mothers primarily receive healthcare information from two sources: health workers during ANC visits, and their families and communities.(17,33) Previous studies have shown that knowledge about HBV risk and the vaccines’ protection is low among Congolese individuals,(17,34) with one study finding a basic knowledge of HBV among only 33.2% of healthcare workers(34) and another finding that only 31.2% (87/280) of pregnant women knew how HBV was transmitted.(35) To increase a mother’s knowledge, initiatives to disseminate vaccine knowledge could be targeted to the mother’s two primary sources of information, the facilities during ANC visits and their communities. In terms of the facility, training that includes vaccine information needs to be geared towards not only vaccine staff, but also the ANC staff who are disseminating information to pregnant women.(17) At the community level, approaches to address the knowledge barrier could be targeted towards the mother’s complete social network of family and friends.(34)

Household wealth status was positively associated with timely BCG vaccination, consistent with other studies.(19,36,37) A possible explanation for this observation is the cost of the vaccinations. Although vaccinations are technically free in the DRC, facilities often require vaccination fees for a vaccine card and well-baby consultation. In addition, indirect costs such as transportation and income loss may act as economic burdens obstructing vaccine uptake.(19,38) The economic burden was further substantiated by our finding that mothers were more likely to vaccinate their infants on time, or ever, if they lived within walking distance to the facility. This finding was confirmed by earlier studies in SSA that distance to facility, travel time, and need for transport were negatively associated with immunization uptake (19,29); one such study found that traveling a distance of over 30 minutes by foot compared to a shorter distance reduced vaccine uptake by one-third.(29) These implications for the enabling factors require policy intervention to reduce the economic burden of infant vaccines, such as transparency and standardization of vaccine costs across facilities and incentives for mothers living beyond walking distance from facilities.

A significant strength of this study was the aggregation of facility-level and individual-level longitudinal data across many facilities. Few studies have looked at a combination of the individual-level determinants of the mother-infant pair and the facility-level determinants of vaccine uptake. The study employs a unique approach to controlling for confounding by using data from both the supply (environment) and demand (mother-infant pair) side. This study's access to longitudinal panel data of over 2,000 women and inventory data about each of the study facilities allowed us to evaluate a comprehensive list of determinants across the BHM levels that determine timely uptake of vaccines. Beyond the unique challenge of administering the vaccine within 24 hours of birth, these determinants highlight the need for an implementation strategy to be rolled out alongside universal HepB-BD. Previous studies demonstrate that timely uptake remains low in countries that have previously adopted HepB-BD because there is no clear guidance to overcome individual- and facility-level challenges.(39,40) Our study's main policy implication was to highlight the barriers to current BD vaccines – and HepB3 vaccine – in a context that strives to include the HepB-BD vaccine in its national immunization schedule. Policymakers may use these findings as evidence when developing a future implementation strategy streamlining all three BD vaccines – HepB-BD, BCG, and OPV0 – within the first 24 hours of life. Findings from this study can help national, sub-national, and facility-level stakeholders to strengthen the uptake of both BD vaccines and other available vaccines for infants across the DRC and SSA.

Despite the study's strengths, it was not without limitations. Our assessment leveraged sample participants from a cohort of women already enrolled in an HIV continuous quality improvement study, which impacted the generalizability of this study. However, vaccine uptake in this population was similar to the national average, and factors influencing vaccine uptake were aligned with other infant immunization studies in the Congo and elsewhere in SSA.(19,29–32,36,37,41) In addition, previous and ongoing studies conducted in the same study clinics observed similar proportions of participants lost to follow up.(21,42) The measure of the outcome variables, vaccine uptake status and timing, may have suffered from recall bias because of the contemporaneous approach of capturing vaccine dates during study interviews. The study staff reviewed infants' vaccine records to correct any errors in logging the vaccine dates to help alleviate any errors. Another limitation of this study is that estimates are not causal but rather represent associations. In addition, only mothers recruited pre-delivery (approximately half of the sample) responded to a question regarding how many ANC visits they had attended because study staff dropped the question among mothers recruited post-delivery. Finally, while the parent study did experience significant rates of LTFU, study staff followed up with respondents to understand reasons for LTFU and recapture some of the data otherwise lost. We were able to weigh LTFU within the 'never vaccinated' rate to represent more accurate rates of failure to vaccinate.

**CONCLUSIONS**

Our findings reveal the factors that most influence timely vaccine uptake of BCG and HepB3 among a cohort of mother-infant pairs across 105 facilities in the Kinshasa Province. We found that higher educational attainment, age, and level of wealth among mothers were positively associated with timely vaccination. In addition, a mother’s proximity/ability to walk to a facility and her choice of facility impacted the status of her infant's vaccine uptake. A mother visiting a facility with higher general and immunization readiness and religious affiliation or private-ownership led to a higher probability of timely infant immunization. Policymakers can use these findings to develop implementation guidance to ameliorate the timely delivery of current BD vaccines and to anticipate potential factors that may impact the future distribution of HepB-BD in the DRC.

**List of abbreviations**

AIC: Akaike’s Information Criterion; ANC: Antenatal care; BCG: Bacille Calmette-Guérin vaccine; BD: Birth-dose; BHM: Andersen Behavioral Health Model; CQI: Continuous quality improvement; DRC: the Democratic Republic of the Congo; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HepB-BD: Hepatitis B birth-dose vaccine; HepB3: Hepatitis B vaccine series; HIV: Human immunodeficiency virus; IQR: Interquartile range; LTFU: Loss-to-follow-up; MTCT: Mother-to-child-transmission; OPV0: Oral polio vaccine; SARA: WHO Service Availability and Readiness Assessment; S.D.: Standard deviation; SSA: Sub-Saharan Africa; UNICEF: United Nations Children’s Fund; WHO: World Health Organization

**DECLARATIONS**

**Ethics approval and consent to participate**

Institutional Review Boards at UNC-Chapel Hill and the Kinshasa School of Public Health approved the study protocol [UNC IRB 21-0014; KSPH IRB ﻿0001 1-04101-00001365292-20]. Participants provided their written, informed consent to participate in the parent study. The parent study was approved by the IRB at Ohio State University, Albert Einstein College of Medicine, and Kinshasa School of Public Health [OSU IRB 2015H0440; Einstein IRB 2020-12018]. Data from the parent study were de-identified prior to analysis and all data were stored on a secure server.

**Consent for publication**

Not applicable.

**Availability of data and materials**

**﻿**The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing Interests**

PT receives research support from ASTMH/Burroughs-Wellcome Fund, Merck, Gilead Sciences and Abbott Laboratories, outside of this work.

**Funding**

This research was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) and the National Institute of Health and Child Development (NIHCD 1R01H087993). MY is partially supported by the National Institutes of Health (NIAID U01AI096299, NICHD R01HD105526). The funders had no role in study design, data collection, data analysis and interpretation, preparation of the manuscript, or decision to submit. PT is funded by a grant from the NIH (NIAID K08AI148607).

**Authors’ contributions**

AB, MY, MED, PT, BF, and CMS designed the study. AB performed the data analysis with contributions from MY, MD, and PT. AB wrote the first draft, with contributions from MY, MED, PT, BF, PN, FL, MT, KM, and PB, and CMS. All authors edited and revised the final manuscript and approved the final version.

**Acknowledgements**

We thank all the women who contributed to the findings of this study. We acknowledge the contribution of the following site investigators of the CQI-PMTCT study team: Godelive Aitikalema, Ali Alisho, Elysée Bayayana, Fabrice Bumwana, Pierre Dianzenza, Jean Claude Dinanga, Georges Kihuma, Willy Lukumu, Fidèle Lumande, Zouzou Masevo, Fanny Matadi, Rachel Mushiya, Marie Therèse Mwela, José Nlandu, Pearl Tenatena, Marie Tshibuabua, Bienvenu Kawende, Christian Mpody, Fatty Malongo Lusambu, Patrick Ngimbi, Jolie Matondo, Sarah Ntambwa, and Noro LR Ravelomanana. We are grateful to the staff of the participating clinics, and to the provincial and national health authorities. We also acknowledge the support we received from the administrative staff of the Ohio State University, Albert Einstein College of Medicine, and the Kinshasa School of Public Health.

**REFERENCES**

1. Centers for Disease Control and Prevention (CDC). Pink Book, Chapter 10: Hepatitis B. 14th ed. 2021.

2. Van Damme P, Kane M, Andre M. Integration of hepatitis B vaccination into national immunisation programmes. Br Med J. 1997;314:1033–5.

3. François G, Dochez C, Jeffrey Mphahlele M, Burnett R, Van Hal G, Meheus A. Hepatitis B vaccination in Africa: mission accomplished? Southern African Journal of Epidemiology and Infection. 2008;23(1):24–8.

4. Breakwell L, Tevi-Benissan C, Childs L, Mihigo R, Tohme R. The status of hepatitis B control in the African region. The PanAfrican Medical journal. 2017;27(Supp 3):17.

5. Tamandjou CR, Maponga TG, Chotun N, Preiser W, Andersson MI. Is hepatitis B birth dose vaccine needed in Africa? The PanAfrican Medical journal. 2017;27(Supp 3:18):1–3.

6. Edmunds WJ, Medley GF, Nokes DJ, O’Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areasr. Epidemiol Infect. 1996;117(2):313–25.

7. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective Efficacy of a Recombinant DNA Hepatitis B Vaccine in Neonates of HBe Antigen—Positive Mothers. JAMA. 1989 Jun 9;261(22):3278–81.

8. Wong VCW, Reesink HW, Ip HMH, Nco Lelie P, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. The Lancet. 1984;1(8383):921–6.

9. Reardon JM, O’Connor SM, Njau JD, Lam EK, Staton CA, Cookson ST. Cost-effectiveness of birth-dose hepatitis B vaccination among refugee populations in the African region: a series of case studies. Confl Health. 2019 Feb 26;13(1).

10. Shimakawa Y, Veillon P, Birguel J, Pivert A, Sauvage V, Guillou-Guillemette H Le, et al. Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study. Lancet Glob Health. 2022;10(4):e521–9.

11. World Health Organization. Practices to improve coverage of the hepatitis B birth dose vaccine. Immunization, Vaccines, and Biologicals. 2013.

12. World Health Organization. Preventing Perinatal Hepatitis B Virus Transmission : A Guide for Introducing and Strengthening Hepatitis B Birth Dose Vaccination. 2015.

13. Njuguna H. Building Toward a Future of African Children Free of HBV Infection: Hepatitis B Virus infection in Africa. In 2021.

14. Boisson A, Goel V, Yotebieng M, Parr JB, Fried B, Thompson P. Implementation Approaches for Introducing and Overcoming Barriers to Hepatitis B Birth-Dose Vaccine in sub-Saharan Africa. Glob Health Sci Pract. 2020;10(1):1–14.

15. Nayagam S, Shimakawa Y, Lemoine M. Mother-to-child transmission of hepatitis B: What more needs to be done to eliminate it around the world? J Viral Hepat. 2020;27(4):342–9.

16. Miyahara R, Jasseh M, Gomez P, Shimakawa Y, Greenwood B, Keita K, et al. Barriers to timely administration of birth dose vaccines in The Gambia, West Africa. Vaccine. 2016 Jun;34(29):3335–41.

17. Boisson A, Morgan CE, Fried B, Shea CM, Yotebieng M, Ngimbi P, et al. Barriers and facilitators to timely birth-dose vaccines in Kinshasa Province, the DRC: a qualitative study. J Glob Health Rep. 2022;6:1–13.

18. World Health Organisation (WHO). National Immunization Schedule Democratic Republic of the Congo. 2018.

19. Sarker AR, Akram R, Ali N, Chowdhury ZI, Sultana M. Coverage and determinants of full immunization: Vaccination coverage among senegalese children. Medicina (Lithuania). 2019;55(8).

20. Yotebieng M, Behets F, Kawende B, Ravelomanana NLR, Tabala M, Okitolonda EW. Continuous quality improvement interventions to improve long-term outcomes of antiretroviral therapy in women who initiated therapy during pregnancy or breastfeeding in the Democratic Republic of Congo: Design of an open-label, parallel, group randomized . BMC Health Serv Res. 2017;17(1):1–7.

21. Zivich PN, Kiketa L, Kawende B, Lapika B, Yotebieng M. Vaccination Coverage and Timelines Among Children 0–6 Months in Kinshasa, the Democratic Republic of Congo: A Prospective Cohort Study. Matern Child Health J. 2017;21(5):1055–64.

22. Wiysonge CS, Uthman OA, Ndumbe PM, Hussey GD. Individual and contextual factors associated with low childhood immunisation coverage in Sub-Saharan Africa: A multilevel analysis. PLoS One. 2012;7(5).

23. World Health Organization (WHO). Reference Manual: Service Availability and Readiness Assessment (SARA) - An annual monitoring system for service delivery. 2015.

24. World Health Organization. Immunization Data portal. 2020 [cited 2021 Dec 20]. Hepatitis B Birth Dose vacination coverage. Available from: https://www.who.int/data/immunization

25. Lancione S, Alvarez JV, Alsdurf H, Pai M, Zwerling AA. Tracking changes in national BCG vaccination policies and practices using the BCG World Atlas. BMJ Glob Health. 2022;7(1):1–8.

26. Phillips DE, Dieleman JL, Shearer JC, Lim SS. Childhood vaccines in Uganda and Zambia: Determinants and barriers to vaccine  coverage. Vaccine. 2018 Jul;36(29):4236–44.

27. Levin A, Munthali S, Vodungbo V, Rukhadze N, Maitra K, Ashagari T, et al. Scope and magnitude of private sector financing and provision of immunization in Benin, Malawi and Georgia. Vaccine. 2019;37(27):3568–75.

28. Zivich PN, Kiketa L, Kawende B, Lapika B, Yotebieng M. Vaccination Coverage and Timelines Among Children 0–6 Months in Kinshasa, the Democratic Republic of Congo: A Prospective Cohort Study. Matern Child Health J. 2017;21(5):1055–64.

29. Ibnouf A, Van den Borne H, Maarse J. Factors influencing immunisation coverage among children under five years of age in Khartoum State, Sudan. South African Family Practice. 2007;49(8):14–14f.

30. Bbaale E. Factors influencing childhood immunization in Uganda. J Health Popul Nutr. 2013;31(1):118–27.

31. Desai S, Alva S. Maternal education and child health: is there a strong causal relationship? Demography. 1998 Feb;35(1):71–81.

32. Mwamba GN, Yoloyolo N, Masembe Y, Nsambu MN, Nzuzi C, Tshekoya P, et al. Vaccination coverage and factors influencing routine vaccination status in 12 high risk health zones in the Province of Kinshasa City, Democratic Republic of Congo (DRC), 2015. The PanAfrican Medical journal. 2017;27(Supp 3):7.

33. Berhanel Y, Bekele A, Tesfaye F. Immunization (EPI) in Ethiopia: acceptance, coverage, and sustainability. Ethiop Med J. 2000;38(Suppl 1):1–60.

34. Shindano TA, Bahizire E, Fiasse R, Horsmans Y. Knowledge, Attitudes, and Practices of health-care workers about viral hepatitis b and C in South Kivu. American Journal of Tropical Medicine and Hygiene. 2017;96(2):400–4.

35. Thahir S, Tulenko SE, Ngimbi P, Ntambua S, Matondo J, Mwandagalirwa K, et al. Low knowledge about hepatitis B prevention among pregnant women in Kinshasa, Democratic Republic of Congo. PLOS Global Public Health. 2022;2(9):e0000450.

36. Herliana P, Douiri A. Determinants of immunisation coverage of children aged 12-59 months in Indonesia: A cross-sectional study. BMJ Open. 2017;7(12):1–14.

37. Fenta SM, Fenta HM. Individual and community-level determinants of childhood vaccination in Ethiopia. Archives of Public Health. 2021;79(1):1–11.

38. Lanaspa M, Balcells R, Sacoor C, Nhama A, Aponte JJ, Bassat Q. The performance of the expanded programme on immunization in a rural area of  Mozambique. Acta Trop. 2015 Sep;149:262–6.

39. Moturi E, Tevi-Benissan C, Hagan J, Shendale S, Mayenga D, Murokora D, et al. Implementing a Birth Dose of Hepatitis B Vaccine in Africa: Findings from Assessments in 5 Countries. J Immunol Sci. 2018;2(SI1):31–40.

40. Adjei CA, Stutterheim SE, Naab F, Ruiter RAC. Chronic Hepatitis B stigma in Ghana: A qualitative study with patients and providers. BMJ Open. 2019;9(6):1–12.

41. Galadima AN, Zulkefli NAM, Said SM, Ahmad N. Factors influencing childhood immunisation uptake in Africa: a systematic review. BMC Public Health. 2021;21(1):1–20.

42. Thompson P, Morgan CE, Ngimbi P, Mwandagalirwa K, Ravelomanana NLR, Tabala M, et al. Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study. Lancet Glob Health. 2021;(21):1–10.